

**AWMSG MEETING TO BE HELD**  
**WEDNESDAY, 12<sup>th</sup> JUNE 2013**  
**COMMENCING 10.30 AM (UNTIL 4.00 PM APPROX)**  
**AT [THE ANGEL HOTEL](#), ABERGAVENNY, NP7 5EN**

**AGENDA**

- |   | <b>Enclosure</b>                  |
|---|-----------------------------------|
| 1. <b>Welcome and introduction</b>  |                                   |
| 2. <b>Apologies</b>   |                                   |
| 3. <b>Declarations of interest</b>  |                                   |
| 4. <b>Chairman's report (verbal update)</b>   |                                   |
| 5. <b>Minutes of previous meeting</b>   | 1/AWMSG/0613                      |
| 6. <b>Appraisal 1 – Full submission<br/>Ceftaroline fosamil (Zinforo<sup>®</sup>) for the treatment of the following<br/>infections: complicated skin and soft-tissue infections (cSSTI)<br/>and community-acquired pneumonia (CAP)</b>   | 2/AWMSG/0613<br><b>Appendices</b> |
| 7. <b>Appraisal 2 – Full submission<br/>Adalimumab (Humira<sup>®</sup>) for the treatment of adults with severe<br/>axial spondyloarthritis without radiographic evidence of<br/>ankylosing spondylitis but with objective signs of<br/>inflammation by elevated CRP and/or MRI, who have had an<br/>inadequate response to, or are intolerant to nonsteroidal anti-<br/>inflammatory drugs</b> | 3/AWMSG/0613<br><b>Appendices</b> |
| <b>Proceedings held in public will close and, to protect commercial confidentiality,<br/>Appraisal 3 will be conducted in private.<br/>The final appraisal recommendation will be announced in public.</b>  |                                   |
| 8. <b>Appraisal 3 – Full submission<br/>C1-esterase inhibitor (Berinert<sup>®</sup>) for the treatment of acute<br/>episodes of hereditary angioedema type I and II (HAE)</b>   | 4/AWMSG/0613<br><b>Appendices</b> |
| 9. <b>Date of next meeting:<br/>Wednesday 17<sup>th</sup> July in Cardiff</b>   |                                   |